Breathe Well Live Well
|
CDISC and TransCelerate BioPharma Inc. Announce Landmark Asthma Data …
PR Newswire (press release) AUSTIN, Texas, Sept. 18, 2013 /PRNewswire/ — The Clinical Data Interchange Standards Consortium (CDISC) and TransCelerate BioPharma Inc. ("TransCelerate"), are pleased to announce that version 1.0 of the Asthma Therapeutic Area (TA) Data Standard … |
View full post on asthma – Google News
REM |
Array Biopharma Inc (NASDAQ:ARRY) attains midstage triumph for asthma …
FinancialsTrend Dallas, Texas 07/24/2013 (Financialstrend) – Array Biopharma Inc (NASDAQ:ARRY) has an additional benefit on deck for a prospective affiliation. The Boulder, CO-based medicine creator has touted upbeat Stage II facts for an experimental medicine in … Biotech News Bundle: BioCryst, NeoStem, Array Biopharma , Lexicon, GTx … Biotech Top Gainers,BioCryst Pharmaceuticals,Array Biopharma,NeoStem … Biotech Stocks Amid Structural And Capital Change: BioCryst Pharmaceuticals … |
View full post on asthma – Google News
|
Shares jump as Array BioPharma reports positive results for asthma drug
The Pharma Letter US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate for mild to moderate persistent allergic asthma, ARRY-502, an oral CRTh2 antagonist, met all primary and secondary endpoints. The company said … |
View full post on asthma – Google News
|
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In …
RTT News Array BioPharma Inc. (ARRY: Quote) announced positive results from a placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary … |
View full post on asthma – Google News
|
Array BioPharma scores midstage success for asthma drug
FierceBiotech Array BioPharma has another asset on deck for a potential partnership. The Boulder, CO-based drug developer has touted upbeat Phase II data for an experimental drug in patients with allergic asthma, and the company ($ARRY) plans to seek a partner to … Array asthma drug meets main goal in mid-stage study Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung … Array Seeks Asthma Drug Partner Following Mid-Stage Study Results |
View full post on asthma – Google News
|
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung …
Wall Street Journal Secondary efficacy endpoints in the proof-of-concept study were also achieved, including reduced short-acting beta agonist use; asthma control; forced vital capacity improvement; symptom-free days during treatment; and improvement in rhinasthma and … Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial |
View full post on asthma – Google News
|
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Benzinga Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to … |
View full post on asthma – Google News
|
Biopharma raising $500K eyes competitive asthma/COPD drug market
MedCity News A biopharmaceutical startup developing a new treatment for asthma that targets the nitric oxide signaling system has raised $50000 of a planned $500000 fundraise, according to recently filed SEC documents. SAJE Pharma LLC's lead compound appears to … |
View full post on asthma – Google News
|
Array BioPharma Reports Results for the Fourth Quarter and Full Year of Fiscal …
MarketWatch (press release) In addition, Array initiated new clinical trials for two proprietary anti-inflammatory drugs: ARRY-797 for pain and ARRY-502 for asthma. ARRY-797 is being tested in a 150-patient Phase 2 chronic pain trial in osteoarthritis (OA) patients with top-line … |
View full post on asthma – Google News